The Efficacy and Safety of Nab-Paclitaxel Plus Gemcitabine versus mFOLFIRINOX in the First-Line Treatment of Metastatic Pancreatic Cancer: A Retrospective Study.
Authors:
Preprint
- 22 August 2022
- preprint
- Published by Springer Nature in Research Square
Abstract
Background Nab-paclitaxel plus Gemcitabine (AG) and modified FOLFIRINOX (FFX) are two systemic therapies that have been widely used as standard first-line chemotherapy regimens in metastatic pancreatic cancer. However, since there is no clinical trial to directly compare the efficacy and safety of the two regimens, it is not clear which regimen is more effective. In this study, we aim to examine and compare the efficacy and safety of AG and FFX as first-line chemotherapy regimens in Chinese patients with metastatic pancreatic cancer in a real-world setting. Methods We retrospectively evaluated the outcomes of 41 patients who diagnosed with metastatic pancreatic cancer and were treated with either AG (n = 21) or FFX (n = 20) as first-line chemotherapy between March 2017 and February 2022 at Zhongnan hospital of Wuhan University. Results Of 41 patients in this study, 21 were treated with AG and 20 were treated with FFX as first-line chemotherapy. No significant differences in baseline characteristics were found between the two groups. The objective response rate (ORR)was 14.3% in the AG group and 20.0% in the FFX group. The disease control rate (DCR) was 71.4% in the AG group and 60.0% in the FFX group. There was no significant difference in PFS or OS between the AG group and the FFX group.The median progression-free survival (PFS) was 5.27 months (95% confidence interval [CI], 4.08–6.46) in the AG group and 3.67 months (95% CI, 2.28–5.05, p = 0.192)in the FFX group.The median overall survival (OS) was 10.03 months (95% CI, 7.33–12.63) in the AG group and 9.02 months (95% CI,6.02–11.98, p = 0.464) in the FFX group.The second-line treatment rate was 47.1% in the AG group and 55.0% in the FFX group. Immune checkpoint inhibitors (ICIs) based regimens are common second-line treatment options whether in AG or FFX group. Significantly more grade 3–4 peripheral neuropathy occurred in the AG than the FFX groups (4 (19.0%) vs 0 (0.0%), p = 0.040*).The patients in the PNI(Prognostic nutrition index) ≥ 45 group had a significant longer median OS (PNI ≥ 45 vs PNI < 45: 10.34 vs 6.90 mo, P = 0.005). Conclusion AG and FFX showed comparable efficacy outcomes in patients with metastatic pancreatic cancer. Pancreatic cancer patients receiving first-line chemotherapy with good nutritional status are likely to have a better prognosis.Keywords
All Related Versions
This publication has 25 references indexed in Scilit:
- Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer TherapyDrug Design, Development and Therapy, 2020
- A systematic review of the effect of preoperative nutrition support on nutritional status and treatment outcomes in upper gastrointestinal cancer resectionEuropean Journal of Surgical Oncology, 2020
- Comparison of FOLFIRINOX and Gemcitabine Plus Nab-paclitaxel for Treatment of Metastatic Pancreatic CancerAmerican Journal of Clinical Oncology, 2020
- Guidelines Insights: Pancreatic Adenocarcinoma, Version 1.2019Journal of the National Comprehensive Cancer Network, 2019
- Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancerCancer Chemotherapy and Pharmacology, 2018
- Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice GuidelineJournal of Clinical Oncology, 2016
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus GemcitabineNew England Journal of Medicine, 2013
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.Journal of Clinical Oncology, 1997
- Prognostic nutritional index in gastrointestinal surgeryThe American Journal of Surgery, 1980